File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Comparison and integration of first trimester fetal nuchal translucency and second trimester maternal serum screening for fetal Down syndrome

TitleComparison and integration of first trimester fetal nuchal translucency and second trimester maternal serum screening for fetal Down syndrome
Authors
KeywordsDown syndrome
Nuchal translucency
Screening
Serum screening
Ultrasound
Issue Date2002
PublisherJohn Wiley & Sons Ltd. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/2252
Citation
Prenatal Diagnosis, 2002, v. 22 n. 8, p. 730-735 How to Cite?
AbstractBackground: It is uncertain whether first trimester nuchal translucency (NT) is more effective than the well-established second trimester serum screening for fetal Down syndrome or whether their combination works best. We report data from a large multicentre non-interventional trial in which all subjects underwent both first and second trimester screening. Methods: All women who attended the obstetric clinic before 15 weeks' gestation were recruited. An ultrasound examination was performed at 10 to 14 weeks to measure the NT. The nuchal measurements were not acted upon unless the fetus showed gross features of hydrops fetalis. All women had serum alpha-fetoprotein (AFP) and human chorionic gonadotrophin (hCG) assay at 15 to 20 weeks. The Down syndrome risk assigned by serum screening was disclosed and amniocentesis was offered if this assigned risk was ≥ 1: 250 or if the women were 35 years and older. The efficacy of different combinations of screening markers was compared. Results: Between January 1997 and August 2000, 17 590 women were recruited (19% ≥ 35 years old). After excluding subjects who miscarried, defaulted the serum test and other reasons, 16 237 pregnancies were analysed. Of these, 35 pregnancies were affected by Down syndrome (2.2 cases per 1000 pregnancies). At a false-positive rate of 5%, the detection rate of Down syndrome by NT alone, NT and age, serum hCG, AFP and age, and NT, hCG, AFP and age were 61%, 69%, 73% and 86%, respectively. Conclusion: Integration of NT and second trimester serum AFP and hCG assay yielded the best screening efficacy for Down syndrome. Copyright © 2002 John Wiley & Sons, Ltd.
Persistent Identifierhttp://hdl.handle.net/10722/87635
ISSN
2015 Impact Factor: 3.043
2015 SCImago Journal Rankings: 1.450
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorLam, YHen_HK
dc.contributor.authorLee, CPen_HK
dc.contributor.authorSin, SYen_HK
dc.contributor.authorTang, Ren_HK
dc.contributor.authorWong, HSen_HK
dc.contributor.authorWong, SFen_HK
dc.contributor.authorFong, DYTen_HK
dc.contributor.authorTang, MHYen_HK
dc.contributor.authorWoo, HHNen_HK
dc.date.accessioned2010-09-06T09:32:22Z-
dc.date.available2010-09-06T09:32:22Z-
dc.date.issued2002en_HK
dc.identifier.citationPrenatal Diagnosis, 2002, v. 22 n. 8, p. 730-735en_HK
dc.identifier.issn0197-3851en_HK
dc.identifier.urihttp://hdl.handle.net/10722/87635-
dc.description.abstractBackground: It is uncertain whether first trimester nuchal translucency (NT) is more effective than the well-established second trimester serum screening for fetal Down syndrome or whether their combination works best. We report data from a large multicentre non-interventional trial in which all subjects underwent both first and second trimester screening. Methods: All women who attended the obstetric clinic before 15 weeks' gestation were recruited. An ultrasound examination was performed at 10 to 14 weeks to measure the NT. The nuchal measurements were not acted upon unless the fetus showed gross features of hydrops fetalis. All women had serum alpha-fetoprotein (AFP) and human chorionic gonadotrophin (hCG) assay at 15 to 20 weeks. The Down syndrome risk assigned by serum screening was disclosed and amniocentesis was offered if this assigned risk was ≥ 1: 250 or if the women were 35 years and older. The efficacy of different combinations of screening markers was compared. Results: Between January 1997 and August 2000, 17 590 women were recruited (19% ≥ 35 years old). After excluding subjects who miscarried, defaulted the serum test and other reasons, 16 237 pregnancies were analysed. Of these, 35 pregnancies were affected by Down syndrome (2.2 cases per 1000 pregnancies). At a false-positive rate of 5%, the detection rate of Down syndrome by NT alone, NT and age, serum hCG, AFP and age, and NT, hCG, AFP and age were 61%, 69%, 73% and 86%, respectively. Conclusion: Integration of NT and second trimester serum AFP and hCG assay yielded the best screening efficacy for Down syndrome. Copyright © 2002 John Wiley & Sons, Ltd.en_HK
dc.languageengen_HK
dc.publisherJohn Wiley & Sons Ltd. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/2252en_HK
dc.relation.ispartofPrenatal Diagnosisen_HK
dc.rightsPrenatal Diagnosis. Copyright © John Wiley & Sons Ltd.en_HK
dc.subjectDown syndromeen_HK
dc.subjectNuchal translucencyen_HK
dc.subjectScreeningen_HK
dc.subjectSerum screeningen_HK
dc.subjectUltrasounden_HK
dc.titleComparison and integration of first trimester fetal nuchal translucency and second trimester maternal serum screening for fetal Down syndromeen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0197-3851&volume=22&spage=730&epage=735&date=2002&atitle=Comparison+and+integration+of+first+trimester+fetal+nuchal+translucency+and+second+trimester+maternal+serum+screening+for+fetal+Down+syndromeen_HK
dc.identifier.emailFong, DYT: dytfong@hku.hken_HK
dc.identifier.emailTang, MHY: mhytang@hkucc.hku.hken_HK
dc.identifier.authorityFong, DYT=rp00253en_HK
dc.identifier.authorityTang, MHY=rp01701en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1002/pd.382en_HK
dc.identifier.pmid12210586en_HK
dc.identifier.scopuseid_2-s2.0-0036023291en_HK
dc.identifier.hkuros69415en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0036023291&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume22en_HK
dc.identifier.issue8en_HK
dc.identifier.spage730en_HK
dc.identifier.epage735en_HK
dc.identifier.isiWOS:000177443300018-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridLam, YH=7202563903en_HK
dc.identifier.scopusauthoridLee, CP=7410149538en_HK
dc.identifier.scopusauthoridSin, SY=7006553270en_HK
dc.identifier.scopusauthoridTang, R=7202300287en_HK
dc.identifier.scopusauthoridWong, HS=7402864769en_HK
dc.identifier.scopusauthoridWong, SF=7404591050en_HK
dc.identifier.scopusauthoridFong, DYT=35261710300en_HK
dc.identifier.scopusauthoridTang, MHY=8943401300en_HK
dc.identifier.scopusauthoridWoo, HHN=36956078200en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats